🇺🇸 FDA
Patent

US 9446048

Methods for treating leukemia and disorders mediated by CBFβ and RUNX1 proteins

granted A61KA61K31/203A61K31/40

Quick answer

US patent 9446048 (Methods for treating leukemia and disorders mediated by CBFβ and RUNX1 proteins) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/203, A61K31/40, A61K31/417, A61K31/5513